UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of March 2020
Commission File Number: 001-37993
OBSEVA SA
(Translation of registrant’s name into English)
Chemin des Aulx, 12
1228 Plan-les-Ouates
Geneva, Switzerland
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
This Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3, as amended (No. 333-233069, 333-222820 and 333-221462) of ObsEva SA (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
Exhibit No. |
|
Description |
99.1 |
|
|
|
|
|
|
|
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
ObsEva SA
|
||||
|
|
|
|
|||||
Date: March 27, 2020 |
|
|
|
By: |
|
/s/ Ernest Loumaye |
||
|
|
|
|
|
|
Name |
|
Ernest Loumaye |
|
|
|
|
|
|
Title: |
|
Chief Executive Officer |
Exhibit 99.1
ObsEva SA: New Date Announcement for AGM
Geneva, Switzerland and Boston, MA – March 27, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health today announced that due to the current situation with COVID-19, the Annual General Meeting previously foreseen to take place in Geneva on May 7th, 2020 has now been delayed until June 9th, 2020, and the related registration deadline has been postponed from April 1st, 2020 to May 4th, 2020 at 22:00 CET.
About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving ET outcomes following IVF. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.
For further information, please contact:
CEO Office contact
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550
Investor Contact
Mario Corso
Senior Director, Investor Relations
mario.corso@obseva.com
+1 857 972 9347 Office
+1 781 366 5726 Mobile
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
DSO+;F4LZ[3 MO8'C.?2LGQ1)+%K&DO#'YDJL2B>IR,"@#J'D2, NZJ#P-QQ5+5],35K+[,\C M1X8,&7GD>WXUF)X8^U/]IU2[EFN2
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